Filter your results
- 2
- 1
- 1
- 3
- 1
- 4
- 1
- 1
- 1
- 1
- 4
- 4
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 4
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
sorted by
|
|
The CD95/CD95L signaling pathway: A role in carcinogenesisCancer Immunology: A Translational Medicine Context, Second Edition, Springer International Publishing, pp.171-188, 2020, 9783030308452. ⟨10.1007/978-3-030-30845-2_11⟩
Book sections
hal-02893414v1
|
||
|
Correction to A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer CellsJournal of Medicinal Chemistry, 2019, 62 (20), pp.9339-9340. ⟨10.1021/acs.jmedchem.9b01578⟩
Journal articles
hal-02526957v1
|
||
|
Downregulation of ceramide synthase-6 during epithelial-to-mesenchymal transition reduces plasma membrane fluidity and cancer cell motilityOncogene, 2015, 34 (8), pp.996-1005. ⟨10.1038/onc.2014.55⟩
Journal articles
hal-01063558v1
|
||
|
The CD95/CD95L signaling pathway: A role in carcinogenesis.BBA - Biochimica et Biophysica Acta, 2014, 1846 (1), pp.130-141. ⟨10.1016/j.bbcan.2014.04.007⟩
Journal articles
hal-01061290v1
|